Form 8-K Summary
Business Context and Reporting Period
The filing was submitted by Blue Water Vaccines Inc., although the request metadata identifies Onconetix, Inc. The report covers an event dated March 29, 2023. Blue Water Vaccines is a Delaware corporation whose common stock traded under the symbol BWV on Nasdaq.
Material Financing Agreement
On March 29, 2023, the company entered into an At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC as sales agent. The program permits the company to sell up to $3.9 million of common stock from time to time.
- The sales agent will receive a 3.0% commission on gross proceeds from each sale.
- Shares may be sold through ordinary broker transactions, including on the Nasdaq Capital Market, at prevailing market prices or at other agreed prices.
- The company is not required to sell shares, and the agent is not required to purchase or sell them.
- Either party may suspend offerings or terminate the agreement as permitted by its terms.
- The shares will be issued under the company’s Form S-3 registration statement, which became effective March 16, 2023, together with the related prospectus supplement filed March 29, 2023.
Financial Metrics and Liquidity
This 8-K does not provide revenue, profit or loss, cash flow, operating margins, debt balances, cash balances, liquidity measures, or other period-end financial results. It also does not state whether any shares had been sold or any proceeds received as of the filing date.
Outlook, Risks, and Unusual Items
The ATM program could provide up to $3.9 million of gross equity financing, subject to market conditions and the company’s decision to sell shares. Actual proceeds would be reduced by the 3.0% sales commission and other potential offering expenses. Issuance of shares may dilute existing stockholders. The filing does not provide management guidance or a broader business outlook.
Investor Verification Items
- Confirm that the filing belongs to Blue Water Vaccines Inc. rather than Onconetix, Inc.
- Review subsequent filings to determine whether shares were sold under the ATM program and the net proceeds received.
- Assess potential dilution relative to the company’s shares outstanding.
- Review the filed At-The-Market Offering Agreement, prospectus supplement, and legal opinion for operative terms.
- Consult later financial statements for the company’s cash position, liquidity needs, debt, and use of any financing proceeds.